|
EconStor >
ifo Institut – Leibniz-Institut für Wirtschaftsforschung an der Universität München >
CESifo Working Papers, CESifo Group Munich >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10419/46570
|
| | |
| Title: | | Do cost-sharing and entry deregulation curb pharmaceutical Innovation?  |
| Authors: | | Grossmann, Volker |
| Issue Date: | | 2011 |
| Series/Report no.: | | CESifo working paper: Public Finance 3439 |
| Abstract: | | This paper examines the role of both cost-sharing schemes in health insurance systems and entry regulation for pharmaceutical R&D expenditure, drug prices, aggregate productivity, and income. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations adversely affect R&D spending in the pharmaceutical sector. In contrast, entry deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies. Extension to an endogenous growth context suggests that, when individual labor supply depends on health status, both cost-sharing and entry barriers in the pharmaceutical sector also affect aggregate productivity and wage rates. |
| Subjects: | | aggregate productivity cost-sharing entry deregulation health insurance pharmaceutical innovation |
| JEL: | | I10 L10 O30 |
| Document Type: | | Working Paper |
| Appears in Collections: | | CESifo Working Papers, CESifo Group Munich
|
| |
| | |
Download bibliographical data as:
BibTeX
|
| |
Share on:http://hdl.handle.net/10419/46570
|
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.
|